A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis

Ravindran, Vinod; Scott, David; Choy, Ernest

doi:10.1136/ard.2007.072652

Cited by 77 publications

(61 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The search strategies were generally adequate to identify both published and unpublished studies, thereby minimising the potential of publication bias. 164,165 However, in the majority of these reviews [158][159][160][161]163 it was unclear whether any language restrictions on study inclusion were made, which may have introduced the possibility of language bias. 166 There were variations in methods of pooling the adverse event data in these reviews.…”

Section: Review Of Adverse Eventsmentioning

confidence: 99%

“…158,162 Statistical heterogeneity 167,168 was adequately assessed in most reviews. In addition, three reviews assessed the adverse events for more than two biologics combined, 158,161,162 whereas the other reviews evaluated them for each biologic respectively. 159,160,163 A range of adverse events of biologics were evaluated in these reviews.…”

Section: Review Of Adverse Eventsmentioning

confidence: 99%

“…Three reviews 160,162,163 evaluated both common and serious adverse events of biologics, whereas two reviews exclusively focused on serious adverse events such as malignancy. 158,159 Two reviews 161,162 used withdrawal rate due to toxicity/adverse events of biologics as the review outcome.…”

Section: Review Of Adverse Eventsmentioning

confidence: 99%

“…Three reviews [158][159][160] included patients with RA and three reviews [161][162][163] included patients with PsA or psoriasis. Almost all reviews evaluated the safety of more than two biologics.…”

Section: Review Of Adverse Eventsmentioning

confidence: 99%

“…166 There were variations in methods of pooling the adverse event data in these reviews. Five reviews 158,159,[161][162][163] used meta-analyses to synthesise the evidence of adverse event data of biologics, whereas one review used a narrative synthesis. 160 For those using meta-analyses, the included studies were combined using either a fixed-effects or random-effects model; one review by Bongartz et al 159 also used the individual patient data (IPD) to pool the results.…”

Section: Review Of Adverse Eventsmentioning

confidence: 99%

See 4 more Smart Citations

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Rodgers

Epstein²,

Bojke³

et al. 2011

Health Technol Assess

155

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. ii ii HTA NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of pro...

show abstract

Section: Review Of Adverse Eventsmentioning

confidence: 99%

Section: Review Of Adverse Eventsmentioning

confidence: 99%

Section: Review Of Adverse Eventsmentioning

confidence: 99%

Section: Review Of Adverse Eventsmentioning

confidence: 99%

Section: Review Of Adverse Eventsmentioning

confidence: 99%

See 3 more Smart Citations

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Rodgers

Epstein²,

Bojke³

et al. 2011

Health Technol Assess

155

View full text Add to dashboard Cite

show abstract

Psoriasis and Related Disorders

Burden

Kirby

2016

Rook's Textbook of Dermatology, Ninth Edition

View full text Add to dashboard Cite

Psoriasis encompasses a group of related immune‐mediated inflammatory skin diseases that affect up to 3% of the population. These diseases are heritable and over 40 genetic susceptibility loci have been identified, many of which are involved in antigen presentation, cytokine signalling or innate antimicrobial responses. The commonest presentation of psoriasis is plaque psoriasis but the disease is clinically hetereogeneous in its manifestations and natural history depending on the age of the patient, environmental triggers and the sites affected. Distinct but related phenotypes include psoriatic arthritis, palmoplantar pustulosis and generalized pustular psoriasis. Psoriasis is associated with co‐morbidities including obesity, diabetes, vascular disease, depression and inflammatory bowel disease, which contribute to the considerable morbidity and increased mortality. Treatments include topical agents for disease of limited extent, phototherapy (UVB, PUVA) and systemic therapy (methotrexate, ciclosporin, acitretin, fumarates) for more extensive disease, and biological treatment (tumour necrosis factor α inhibitors, ustekinumab) for severe resistant psoriasis.

show abstract

Psoriasis and Related Disorders

Kirby,

Burden

2024

Rook's Textbook of Dermatology

View full text Add to dashboard Cite

A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis

Abstract: Efficacy/toxicity ratios were highest with TNF inhibitors followed by leflunomide, gold and sulfasalazine. Gold, though effective, has excessive toxicity and sulfasalazine, though of low toxicity, was also relatively ineffective.

Cited by 77 publications

References 41 publications

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Psoriasis and Related Disorders

Psoriasis and Related Disorders

Contact Info

Product

Resources

About